Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Chief Commercial Officer | April 17, 2025 | April 21, 2025 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Chief Commercial Officer | September 21, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Esperion Therapeutics, Inc.
Report date April 17, 2025 · Filed April 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 370,218 |
Reported balance
After 2025-04-17 transaction · row 1
1 source rowRow 1 · 2025-04-17 · Sale · Disposed 108 · Balance 370,218 F1: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Mineralys Therapeutics, Inc.
Report date September 21, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,400 |
Ending reported balance
After 2026-09-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-21 · Exercise / conversion · Acquired 7,438 · Balance 45,838 F1: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Row 2 · 2026-09-21 · Sale · Disposed 7,438 · Balance 38,400 F1: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.24 · Expires 2035-04-21 | Direct | 230,563 |
Reported balance
After 2026-09-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-21 · Exercise / conversion · Disposed 7,438 · Balance 230,563 F1: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F3: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2026 Filed Sep 22, 2026 22:48 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 7,438 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001916048-26-000014 · wk-form4_1790117313.xml · derivative · entry 3 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,563 Underlying: Common Stock · 7,438 shares Expires 2035-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 22:48 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 7,438 | $28.12 | $209,135.73 |
DisclosureSEC source: 0001916048-26-000014 · wk-form4_1790117313.xml · nonDerivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,400 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 22:48 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 7,438 | $13.24 | $98,479.12 |
DisclosureSEC source: 0001916048-26-000014 · wk-form4_1790117313.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 21:16 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 7,437 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001916048-26-000012 · wk-form4_1787692603.xml · derivative · entry 3 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,001 Underlying: Common Stock · 7,437 shares Expires 2035-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 21:16 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 7,437 | $25.98 | $193,188.72 |
DisclosureSEC source: 0001916048-26-000012 · wk-form4_1787692603.xml · nonDerivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,400 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 21:16 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 7,437 | $13.24 | $98,465.88 |
DisclosureSEC source: 0001916048-26-000012 · wk-form4_1787692603.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 22:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 7,438 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001916048-26-000009 · wk-form4_1784846362.xml · derivative · entry 3 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,438 Underlying: Common Stock · 7,438 shares Expires 2035-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 22:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 7,438 | $26.87 | $199,885.09 |
DisclosureSEC source: 0001916048-26-000009 · wk-form4_1784846362.xml · nonDerivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,400 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 22:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 7,438 | $13.24 | $98,479.12 |
DisclosureSEC source: 0001916048-26-000009 · wk-form4_1784846362.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 22:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 104,124 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001933414-26-000095 · wk-form4_1782859276.xml · derivative · entry 3 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 252,876 Underlying: Common Stock · 104,124 shares Expires 2035-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 22:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 104,124 | $25.90 | $2,696,322.22 |
DisclosureSEC source: 0001933414-26-000095 · wk-form4_1782859276.xml · nonDerivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,400 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 22:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 104,124 | $13.24 | $1,378,601.76 |
DisclosureSEC source: 0001933414-26-000095 · wk-form4_1782859276.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 20:04 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 108 | $0.98 | $105.62 |
DisclosureSEC source: 0001628280-25-018567 · wk-form4_1745265839.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,218 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 20:02 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 2,433 | $1.49 | $3,617.87 |
DisclosureSEC source: 0001628280-25-013811 · wk-form4_1742414564.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,326 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:16 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 191,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001628280-25-013196 · wk-form4_1742246176.xml · derivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,000 Underlying: Common Stock · 191,000 shares Expires 2035-03-14 F1 · derivative.exercise_date: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be on June 15, 2025. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:16 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 213,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-013196 · wk-form4_1742246176.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,759 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be on June 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:50 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 239 | $1.87 | $446.45 |
DisclosureSEC source: 0001628280-25-006802 · wk-form4_1740088238.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,759 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 21:37 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 123 | $2.26 | $277.98 |
DisclosureSEC source: 0001628280-25-002035 · wk-form4_1737495469.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,998 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 21:13 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 2,234 | $2.43 | $5,426.39 |
DisclosureSEC source: 0001628280-24-051870 · wk-form4_1734556418.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,121 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:10 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 197 | $2.17 | $426.51 |
DisclosureSEC source: 0001628280-24-048659 · wk-form4_1732137047.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,355 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 20:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 107 | $2.12 | $226.73 |
DisclosureSEC source: 0001628280-24-043107 · wk-form4_1729282120.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,552 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:11 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 2,608 | $1.78 | $4,650.06 |
DisclosureSEC source: 0001628280-24-040785 · wk-form4_1726690311.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,659 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 211 | $1.95 | $410.61 |
DisclosureSEC source: 0001628280-24-037887 · wk-form4_1724184206.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,267 F1 · balance_after: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 12:30 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 108 | $2.59 | $279.40 |
DisclosureSEC source: 0001628280-24-032268 · wk-form4_1721392213.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,478 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:16 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 2,540 | $2.86 | $7,254.24 |
DisclosureSEC source: 0001628280-24-029114 · wk-form4_1718914583.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,586 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:14 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 192 | $2.48 | $476.74 |
DisclosureSEC source: 0001628280-24-024346 · wk-form4_1716236074.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,126 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:35 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001628280-24-011494 · wk-form4_1710534908.xml · derivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-03-14 F1 · derivative.exercise_date: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be on June 15, 2024. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:35 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011494 · wk-form4_1710534908.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,318 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be on June 15, 2024. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 21:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 742 | $1.25 | $923.79 |
DisclosureSEC source: 0001628280-23-032795 · wk-form4_1695330364.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,318 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:32 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 243 | $1.41 | $343.60 |
DisclosureSEC source: 0001628280-23-030129 · wk-form4_1692649904.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,060 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 20:38 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 106 | $1.59 | $168.01 |
DisclosureSEC source: 0001628280-23-025248 · wk-form4_1689885499.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,303 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 20:45 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 603 | $1.48 | $894.25 |
DisclosureSEC source: 0001628280-23-023157 · wk-form4_1687466704.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,409 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:07 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 219 | $1.62 | $355.66 |
DisclosureSEC source: 0001628280-23-018872 · wf-form4_168444041471189.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,012 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 20:12 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 115 | $1.28 | $146.97 |
DisclosureSEC source: 0001628280-23-012265 · wf-form4_168202156208560.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,231 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 20:16 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 526 | $1.78 | $937.49 |
DisclosureSEC source: 0001628280-23-008609 · wf-form4_167934336969120.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,346 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 13:22 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 94,500 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001628280-23-007970 · wf-form4_167888654616429.xml · derivative · entry 2 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Underlying: Common Stock · 94,500 shares Expires 2033-03-14 F2 · derivative.exercise_date: Such options will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 13:22 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 22,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-007970 · wf-form4_167888654616429.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,872 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 21:22 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 5,090 | $5.06 | $25,729.95 |
DisclosureSEC source: 0001628280-23-006992 · wf-form4_167831051271071.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,572 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of performance-based restricted stock units. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:11 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 107 | $7.69 | $822.83 |
DisclosureSEC source: 0001628280-22-026631 · wf-form4_166621025881204.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,662 F1 · shares: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 20:09 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 255 | $6.92 | $1,764.86 |
DisclosureSEC source: 0001628280-22-025218 · wf-form4_166370453726031.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,769 F1 · shares: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units. Read SEC document |
| August 31, 2022 Filed Aug 31, 2022 20:14 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 1,000 | $7.46 | $7,460.00 |
DisclosureSEC source: 0001628280-22-024059 · wf-form4_166197686284070.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,024 Read SEC document |
| August 17, 2022 Filed Aug 18, 2022 20:10 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 199 | $6.82 | $1,356.19 |
DisclosureSEC source: 0001628280-22-023250 · wf-form4_166085341182828.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,024 F1 · shares: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:27 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 431 | $6.58 | $2,836.84 |
DisclosureSEC source: 0001628280-22-019179 · wf-form4_165834881315059.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,223 F1 · shares: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 256 | $4.90 | $1,254.40 |
DisclosureSEC source: 0001628280-22-017640 · wf-form4_165584197584984.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,654 F1 · shares: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:46 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001628280-22-016703 · wf-form4_165480759498402.xml · derivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: Such award shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:30 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 196 | $5.98 | $1,172.28 |
DisclosureSEC source: 0001628280-22-014762 · wf-form4_165290519246954.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,910 F1 · shares: Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 21:11 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-006410 · wf-form4_164746503326063.xml · nonDerivative · entry 1 Warren Eric · CIK 0001916048 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,106 F1 · shares: The awards will vest quarterly over four years beginning on March 15, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.